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Post marketing surveillanceAbstract Background: Adverse drug reactions (ADRs) are a major cause of drug related morbidity
and mortality. Pharmacovigilance is the science that plays an essential role in the reduction of ADRs,
thus the evolution and growth of this science are critical for effective and safe clinical practice.
Objectives: This study is considered the ﬁrst study in the region to evaluate pharmacist’s knowl-
edge, practice and attitudes toward ADRs reporting after establishing the national ADRs reporting
center in Jordan.
Method: A cross sectional study was used to evaluate pharmacist knowledge and attitude toward
ADRs reporting. A structured validated questionnaire was developed for this purpose and a total of
208 pharmacists were recruited to participate in this study.
Results: The majority of pharmacists have insufﬁcient awareness and lack of knowledge about
pharmacovigilance andADRs reporting.Also the rate of reporting ofADRswas extremely poor. Sev-
eral factors were found to discourage pharmacists from reporting ADRs, which include inadequate
information available from the patient, unavailability of pharmacist ADRs form when needed,
unawareness of the existence of the national ADRs reporting system. Also pharmacists think that
ADRs are unimportant or they did not know how to report them.
Conclusion: The results of this study suggest that pharmacists have insufﬁcient knowledge about
the concept of pharmacovigilance and spontaneous ADRs reporting. On the other hand, pharmacists
had positive attitudes toward pharmacovigilance, despite their little experience with ADRs reporting.
Educational programs are needed to increase pharmacist’s role in the reporting process, and thus to
have a positive impact on the overall patient caring process.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Adverse drug reactions (ADRs) are a major cause of patient
related morbidity and mortality (Lee and Thomas, 2007),
and they are associated with a high prevalence of hospital
148 M. Suyagh et al.admission reaching about 6.5% as well as a considerable eco-
nomic burden; in which around £466 million was reported as
an annual total cost for drug related admissions in the united
kingdom (Pirmohamed et al., 2004). Thus reporting of ADRs
is considered to be an important step in maintaining and
achieving a safe drug therapy use.
Most countries developed their national pharmacovigilance
systems after the thalidomide disaster in 1960s (Rawlins,
1995). World Health Organization (WHO) has established
the deﬁnition of pharmacovigilance as ‘‘the science and activ-
ities relating to the detection, assessment, understanding and
prevention of adverse effects or any other possible drug-related
problems’’ (WHO, 2002). Pharmacovigilance plays an essential
role in the reduction of ADRs, thus the evolution and growth
of this science are critical for effective and safe clinical practice.
ADRs spontaneous reporting systems are the basic compo-
nents for the comprehensive post-marketing surveillance of
drug-induced risks (Stricker and Psaty, 2004). These systems
are inexpensive and simple to operate and they enable the gen-
eration of signals indicating potential problems, allowing the
identiﬁcation of new and rare ADRs, but also enable continu-
ous monitoring of all drugs used in real life situations from the
time they are ﬁrst marketed. However, their strength is tightly
connected to the actual reporting rate by health care profes-
sionals (Wiholm et al., 2002).
All sectors of the healthcare system would need to be
involved in the reporting process, such as public and private
hospitals, general practitioners, nurses, retail dispensaries,
and pharmacists. Wherever medicines are being used, there
should be a readiness to observe and report unwanted adverse
events (both expected and unexpected) (WHO, 2002, 2004).
Pharmacists were found to have an important role in ADRs
reporting, and constitute a potentially valuable source for
spontaneous ADRs reports (Kaboli et al., 2006; van
Grootheest et al., 2004). However, under-reporting of ADRs
is a main intrinsic problem, in which reporting of serious
ADRs rarely exceeds 10% (Granas et al., 2007; Su et al.,
2010; Toklu and Uysal, 2008; Vessal et al., 2009). It was found
that the main reasons for poor reporting rate were either due
to legislative restrictions or because of lack of tradition (van
Grootheest and de Jong-van den Berg, 2005; van Grootheest
et al., 2004).
The Jordanian Pharmacovigilance Center (JPC) was estab-
lished in January 2001 in cooperation with Sweden Interna-
tional Development Agency (SIDA) and the Higher Council
for Science and Technology (Yadav, 2008). Since that time,
no studies have assessed pharmacists’ knowledge and attitudes
toward ADRs reporting in the hospital and community
settings in Jordan. Our study was in the unique position to
study pharmacist’s attitudes toward ADRs reporting after
the initiation of the national ADRs reporting center and their
understanding and knowledge of the yellow card spontaneous
ADRs reporting scheme.2. Methodology
2.1. Study design, settings and study subjects
This is a cross-sectional study that was conducted in two of the
largest cities in Jordan; Amman and Zarqa. The study
commenced in July-2012 and continued for two months.Two hundred and eight pharmacists (both community and
hospital pharmacists) were included in the study with a
response rate of 96.7%. Each pharmacist was asked to ﬁll a
validated structured questionnaire delivered by hand. The par-
ticipated pharmacists were from independent and chain phar-
macies as well as from different hospitals (public and private
hospitals). Sixteen hospitals in Amman and Zarqa were cov-
ered, while the community pharmacies coverage represented
about 5.2 % of the total number of pharmacies in Jordan.
2.2. Questionnaire
Content validity was assessed by distributing the questionnaire
to 10 pharmacists recruited to complete the validation process.
The initial draft of questionnaire was hand delivered to those
pharmacists to help review the structured questionnaire and
perform any amendments needed.
The ﬁnal form of the questionnaire consisted of pharmacist
demographic data, and a total of 20 questions that covered
three main areas of interest. These areas included: (1) assess-
ment of pharmacist knowledge regarding pharmacovigilance
and ADRs reporting, (2) pharmacist’s attitude and practice
toward ADRs reporting process and (3) pharmacists’ recom-
mendations and suggestion to improve the drawback in the
system.
2.3. Statistical analysis
Data were analyzed using statistical package for social science
version 17 (SPSS, Inc., Chicago, IL, USA). The descriptive
analysis was done using mean and SD for continuous variables
and percentage for qualitative variables. Pearson Chi- Square
was used to calculate p-values for categorical variables.3. Results
3.1. Demographics
The demographic details of the pharmacists included in the
study are shown in Table 1. The mean age of pharmacist was
approximately 32 years, and the average year of experience
was 7.83 years. In this study, 62.5% of pharmacists were com-
munity pharmacists while 37.5 % were hospital pharmacists.
Females accounted for 63.9% of pharmacists.
3.2. Pharmacist knowledge regarding pharmacovigilance and
ADR reporting
This questionnaire contained two open-ended questions in
which the pharmacists were asked to deﬁne the terms ‘pharma-
covigilance’ and ‘adverse drug reaction’. Of the responding
pharmacists, only 25.5% deﬁned ‘pharmacovigilance’ correctly
while 69.7% deﬁned ADR correctly. Hospital pharmacists
showed better awareness of the concept of pharmacovigilance
compared with the community pharmacists (p-value less than
0.05), while there is no signiﬁcant difference found between
the two groups for the deﬁnition of ADR. Only 8.2% had
attended a workshop regarding how to report an ADR.
Most of pharmacists were not aware of the presence of
legal provisions in the medicines act that provide for
Table 1 Demographic characteristic of the study sample
(n= 208).
Parameter Results
Age [years; mean (SD)] 32.13 (8.76) [min: 22, max: 70]
Gender [female; N (%)] 133 (63.9%)
Years of practice [years; mean (SD)] 7.83 (8.07) [min: 0.1, max: 45]
Site of work; N (%)
 Community pharmacists 130 (62.5%)
 Hospital pharmacists 78 (37.5%)
Educational level; N (%)
 BSC. in pharmacy 162 (77.9%)
 Pharm. D 24 (11.5%)
 Masters 22 (10.6%)
 PhD 0 (0%)
Pharmacovigilance 149pharmacovigilance activities (63.1%), and most of them did
not know that we have a pharmacovigilance center in Jordan
and an ofﬁcial standardized form for reporting adverse drug
reactions (84.5% and 71.5%, respectively). Again hospital
pharmacists knew signiﬁcantly more than community pharma-
cists regarding the previous issues (p-value less than 0.05). The
results are presented in Table 2.
3.3. Pharmacist practice and attitude toward ADRs reporting
The overall rate of ADRs reporting by pharmacists is shown in
Table 3. It is obvious that about 91.2% of the pharmacists had
noticed at least one ADR in a patient per a year, while only
19.5% had ever reported an ADR.
When pharmacists were asked about what they must do if
they want to report an ADR, approximately 76% of pharma-
cists admitted that they did not know from where they couldTable 2 Assessment of pharmacist knowledge about pharmacovigi
Questions$
Have you ever heard about the concept of
pharmacovigilance?
Yes
What is the deﬁnition of pharmacovigilance?
Correct Answer
What is the deﬁnition of adverse drug reaction?
Correct Answer
Have you ever had a course/attended a workshop
about pharmacovigilance?
Yes
In Jordan, are there legal provisions in the medicines
act that provide for pharmacovigilance activities?
Yes
In Jordan, is there pharmacovigilance center?
Yes
In Jordan, is there an oﬃcial standardized form for
reporting adverse drug reactions?
Yes
$ Question answers were either Yes or No.
* Signiﬁcant difference.
** Percentage within group.get the ADRs reporting forms, and almost all of them
(98.5%) did not know the period within which they should
report serious ADRs experienced by a patient. The question-
naire revealed that 55.1% of the pharmacists believed that if
they want to report ADRs they will send their report to the
Jordan food and drug administartion (JFDA) which is the
authorized organization for reporting ADRs in Jordan.
When pharmacists were asked about their preferred method
of reporting, 33.3% of them believed that using a speciﬁc form
was their preferred method of reporting, while 23.2%, 25.6%,
and 4.3% preferred to report via phone calls to the drug
company, informing the representative of the drug company
verbally or by using internet.
Pharmacists also were asked about their ﬁrst actions if they
were in a situation dealing with patients with severe ADRs.
Fig. 1 shows that only 6% of the pharmacists tend to report
severe ADRs immediately and the majority of them preferred
to contact the physician (27%), direct the patient to an
emergency room (24%) or ask the patient to contact the
physician (22%).
Pharmacists were also asked to determine their degree of
agreement regarding their responsibilities in reporting ADRs.
This was done in order to assess their beliefs about the impor-
tance of their profession in the pharmacovigilance system, and
the responsibility of the pharmacist, physician, nurses, drug
company and patient in ADRs reporting. The scale consisted
of three levels: (1: disagree; 2: uncertain; 3: agree). Twenty-ﬁve
percent of pharmacists believed that their role in the pharma-
covigilance system is important. The responsibility order was
as the following: pharmacist (95.2%), physician (90.8%), drug
company (86.8%), patient (74.9%) and nurses (71.3%). The
results are presented in Fig. 2.
Table 4 shows the perception of pharmacists toward the










36 (27.7%) 35 (44.9%) 0.011*
25 (19.2%) 28 (35.9%) 0.008*
88 (67.7%) 57 (73.1%) 0.413
7 (5.4%) 10 (12.8%) 0.058
41 (31.5%) 35 (46.1%) 0.037*
10 (7.7%) 22 (28.6%) 0.000*
19 (14.6%) 40 (51.9%) 0.000*
Table 3 Pharmacist practices toward ADRs reporting procedure.
Question Number of respondent %
How often do the patients report you ADRs of medications? 204
More than once a week 26.5
Once a month 27.9
A few times a year 36.8
Never 8.8
Have you ever reported any ADR? 205
Yes 19.5
No 80.5
Do you know from where can you get the ADRs reporting form? 208
Yes 26.0
No 74.0
Do you know what is the period within which you should report a serious ADR experienced by a patient? 205
Yes 1.5
No 98.5
Do you know to whom you should report the ADRs? 207
The Ministry of health (MOH) 16.4
The Jordanian pharmaceutical association 6.3




How do you prefer to report the ADRs? 207
A phone call to drug company 23.2
Verbally inform the representative of the drug company on routine visits 25.6
Mail via internet 4.3
Using adverse drug reaction reporting form 33.3
Other (specify) 13.5
150 M. Suyagh et al.majority of pharmacists believed that reporting ADRs is an
important mission provided by pharmacists.
Factors inﬂuencing and encouraging the pharmacists to
report ADRs were evaluated in this study. Table 5 shows that
most of pharmacist preferred to report reaction of serious nat-
ure (but this was contradictory to their actual action), also
most of them preferred to report unusual reactions and reac-
tions that have been not reported before.
An interesting observation here is that nearly half of the
pharmacists were reluctant to report reactions for a new drug
as well as well recognized reactions.
Factors that may discourage the pharmacists to report
ADRs were also evaluated. The main ﬁve reasons that discour-
age the pharmacists from reporting ADRs were ‘‘no enough
information available from the patient (76.7%)’’, ‘‘Pharma-
cist’s ADRs form is not available when needed (72.5%)’’,
‘‘unawareness of the existence of a national ADRs reporting
system (70.7%)’’, ‘‘The ADR is too trivial to report (67.1%)
and ‘‘ they did not know how to report (66.7%)’’. The results
are presented in Table 6.
3.4. Pharmacists’ recommendations and suggestion to improve
the drawback in the system
The majority of pharmacists who participated in this study
(both hospital and community pharmacists), recommended
that there is a need to raise pharmacists awareness toward
pharmacovigilance and mainly toward ADRs reporting pro-
cess. They suggested to include this topic as a part of teaching
curriculum, as well as to perform a number of educational
courses and workshops by the specialized authorities.4. Discussion
The main aim of this study was to evaluate the attitudes and
knowledge of pharmacists toward pharmacovigilance and
spontaneous ADRs reporting. There are several reports from
different countries which commonly emphasize the problem
of the ADRs under-reporting among pharmacists (Generali
et al., 1995; Granas et al., 2007; Green et al., 2001; Herdeiro
et al., 2006; Lee et al., 1994; Sweis and Wong, 2000; Toklu
and Uysal, 2008). To the best of our knowledge, this cross-sec-
tional survey is the ﬁrst study to evaluate this issue in Jordan.
The results of the present study ﬁrstly demonstrated that
the majority of pharmacists have insufﬁcient knowledge and
lack of awareness about pharmacovigilance and ADRs report-
ing systems. The results of this study were consistent with a
previous report by Toklu and Uysal in which they showed that
82.5% of the pharmacists were not aware of the concept of
pharmacovigilance (Toklu and Uysal, 2008).
Despite the lack of knowledge in the majority of pharma-
cists, the study showed that the awareness of hospital pharma-
cists was better compared to community pharmacists which
may be related to the fact that hospital pharmacists are in
direct contact with other health care professionals such as phy-
sicians and nurses who are more often involved in the identiﬁ-
cation of potential ADRs, thus they are more exposed to
situations where there is a need to manage or to report such
adverse effects. In a study by Herdeiro et al., it was shown that
hospital pharmacists report 20 times more frequently than
community pharmacists, this was due to the fact that the hos-
pital pharmacist was better educated and informed about
pharmacovigilance practice (Herdeiro et al., 2006).
Figure 1 Initial actions that may be performed by pharmacists when dealing with patients with severe ADRs.
Figure 2 Pharmacist’s level of agreement following asking them about health care professional’s responsibility toward ADRs reporting.
Pharmacovigilance 151Lack of knowledge is considered the starting point to deal
with the problem of under reporting of ADRs, since it was
previously shown that pharmacist knowledge exerted a strong
inﬂuence on ADRs reporting (Herdeiro et al., 2006).
Accordingly, we can expect to have a low rate of ADRs
reporting secondary to poor knowledge of reporting
procedures, which is consistent with what we found in our
study. The rate of reporting of ADRs was extremely poor, with
only 19.5% of study participants ever reporting an adverse
effect. Therefore, if we suppose that those pharmacists
reported only one or few ADRs during their practice, this
means that the overall rate of reporting serious and actual
ADRs is extremely poor.
The main reason for this low rate of reporting is the lack of
knowledge, in which a large number of study participants
admitted that they did not know how to report an ADR and
if there is a legal authority to report to, they also did not know
from where they could get the ADRs reporting forms, and theperiod within which they should report a serious ADRs expe-
rienced by the patient.
The majority of study participants considered ADRs
reporting to be a natural task for pharmacists, as well as main
responsibility of all healthcare providers, but the pharmacist
was ranked to be the most important provider in preventing
ADRs reporting. In the developing countries, pharmacists play
an active role in patient medication management process, and
patients prefer to contact them ﬁrst for any consultation
because they easily accessed healthcare providers. Therefore,
pharmacists need to take a more active role in the assessment
and decision making concerning the safety of patient medica-
tions (van Grootheest et al., 2004). Pharmacist’s role in phar-
macovigilance may vary from country to country, but the
professional responsibility is the same, regardless of jurisdic-
tion (Roberts et al., 1994).
Regarding pharmacist perception and attitude toward
ADRs reporting, pharmacists showed almost positive attitude









1. Level of clinical knowledge makes it diﬃcult to decide whether
or not an ADR has occurred
61.4 5.3 33.3 207
2. Uncertain association between the drug and the adverse
reaction
54.3 10.7 35.0 206
3. The ADR is too trivial to report 67.1 7.3 25.6 207
4. Concern that a report will generate extra work 33.2 12.0 54.8 208
5. Pharmacist’s adverse drug reaction form is not available when
needed
72.5 7.7 19.8 207
6. Lack of conﬁdence in discussing the ADRs with the prescriber 39.9 10.1 50.0 208
7. No enough information available from the patient 76.7 11.7 11.7 206
8. Lack of time to ﬁll in a report 32.2 14.9 52.9 208
9. Unaware of the existence of a national ADR reporting system 70.7 9.8 19.5 205
10. Did not know how to report 66.7 9.2 24.2 207
11. Fear of legal liability 30.3 10.1 59.6 208
12. Unaware of the need to report an ADR 36.4 7.8 55.8 206
13. Lack of ﬁnancial reimbursement 14.9 5.8 79.3 208
14. Consider it the doctors’ responsibility 17.9 7.7 74.4 207
Table 4 Pharmacists’ perception of the importance of ADRs reporting.
Purpose Agree % Uncertain % Disagree % No. of respondent
1. To enable safe drugs to be identiﬁed 96.6 1.9 1.4 208
2. To measure the incidence of ADRs 96.6 2.4 1.0 208
3. To identify factors that might predispose to an ADR 96.1 3.9 0.0 207
4. To identify previously unrecognized ADRs 97.1 2.9 0.0 208
5. To compare ADRs for drugs in similar therapeutic classes 93.7 5.3 1.0 207
6. To compare ADRs of the same drug from diﬀerent drug companies 84.1 7.7 18.2 208
Table 5 Factors that may encourage pharmacists to report ADRs.
Agree % Uncertain % Disagree % No. of respondent
1. The reaction is of a serious nature 99.0 0.0 1.0 208
2. The reaction is unusual 97.6 1.9 0.5 208
3. The reaction is to a new product 57.0 14.5 28.5 207
4. Reaction not reported before for a particular drug 87.9 9.7 2.4 207
5. Reaction is well recognized for a particular drug 57.0 14.5 28.5 208
152 M. Suyagh et al.toward ADRs reporting process despite the low reporting rate,
a pattern similar to other studies (Granas et al., 2007; Lee
et al., 1994; Toklu and Uysal, 2008). Attitudes are potentially
modiﬁable variables exerting a strong inﬂuence on ADRs
reporting (Herdeiro et al., 2006), the greater the patient atti-
tude the more positive inﬂuence on the overall ADRs reporting
rate. This issue was proved previously by Granas et al., in
which they have shown that an educational program can sig-
niﬁcantly modify pharmacists’ reporting-related attitudes and
inﬂuence the ADRs reporting behavior in a positive manner
(Granas et al., 2007).
In this study it is obvious that among the factors that
encourage pharmacists to report ADRs is the nature and
severity of the ADRs. Pharmacists preferred to report reac-
tions of serious nature as well as unusual reactions and reac-
tions that have not been reported before. On the other hand
they were reluctant to report well known ADRs, a ﬁnding thatconﬁrms results of previous studies (Eland et al., 1999; Granas
et al., 2007; Hasford et al., 2002). However, the spontaneous
reporting system could be used as a tool for monitoring
changes of the type and/or frequency of serious known ADRs.
Several factors were found to discourage pharmacists from
reporting ADRs, which include no enough information avail-
able from the patient, unavailability of pharmacists ADRs
form when needed, unawareness of the existence of a national
ADRs reporting system, the ADR is too trivial to report and
they did not know how to report. These ﬁndings were similar
to results of a study performed on pharmacists in Iran. These
ﬁndings were similar to results of a study performed on phar-
macists in Iran (Vessal et al., 2009), which found that the main
reasons for not reporting of ADRs were uncertain association,
too trivial ADRs to report, too well known ADRs to report,
and yellow card not available. Also another study performed
on pharmacists of the Turkish community found that the most
Pharmacovigilance 153common reasons for not reporting ADRs were lack of knowl-
edge of how to reach ADRs forms, and not being mandatory
(Toklu and Uysal, 2008).
This study explored the urgent need for educational pro-
grams to emphasize the role and responsibility of pharmacists
in pharmacovigilance practices, and to raise awareness toward
ADRs reporting process. Most probably, all these perceptions,
attitude and behaviors could be changed signiﬁcantly by
proper educational programs as was previously shown by
Granas et al. 2007. However, we are aware of some methodo-
logical weaknesses of our study; as the questionnaire relied on
pharmacists’ self-rated assessment of their own practice and
attitudes, pharmacists might have felt pressured into complet-
ing the questionnaire or might have been unwilling to reveal
their practice deﬁciencies. Also the research has been con-
ducted over a short period of time, which might shed doubt
on the objectivity of the responses and introducing some over
estimation in both pharmacist’s knowledge and attitudes.5. Conclusion
These results suggest that Jordanian pharmacists have little
knowledge about the concept and process of pharmacovigi-
lance and spontaneous ADRs reporting system. However the
pharmacists had positive attitudes toward pharmacovigilance,
but very little experience with reporting. Educational programs
are needed to increase pharmacists’ role and their knowledge
about the reporting process and its requirements, and thus to
have a positive impact on patient caring process.6. Conﬂict of interest
None.
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